1. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models
- Author
-
Marieke Lamers, Grant Wishart, Karen Barnes, Graham D. Smith, Ivan Angulo-Herrera, Sarah L. Martin, Rebecca E. Jarvis, Wesley Blackaby, Philip Leonard, Ovadia Lazari, Leticia Toledo-Sherman, David F. Fischer, Maria Eznarriaga, Simon J. Dowler, George McAllister, Rhea van de Bospoort, Dawn Yates, Annelieke Strijbosch, Helen C. Cox, Jennifer R. Bate, Esmieu William R K, Amanda Van de Poël, Roger Cachope, Sung-Wook Jang, Perla Breccia, Celia Dominguez, Mark Rose, Kim L. Matthews, Huw D. Vater, Stephen D. Penrose, and Ignacio Munoz-Sanjuan
- Subjects
Ataxia ,Huntingtin ,Mutant ,Ataxia Telangiectasia Mutated Proteins ,01 natural sciences ,Proof of Concept Study ,Madin Darby Canine Kidney Cells ,03 medical and health sciences ,Mice ,Dogs ,Huntington's disease ,In vivo ,Drug Discovery ,medicine ,Animals ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Kinase activity ,030304 developmental biology ,0303 health sciences ,Chemistry ,medicine.disease ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Disease Models, Animal ,Huntington Disease ,Neuroprotective Agents ,Toxicity ,Cancer research ,Molecular Medicine ,Phosphorylation ,medicine.symptom - Abstract
Genetic and pharmacological evidence indicates that the reduction of ataxia telangiectasia-mutated (ATM) kinase activity can ameliorate mutant huntingtin (mHTT) toxicity in cellular and animal models of Huntington's disease (HD), suggesting that selective inhibition of ATM could provide a novel clinical intervention to treat HD. Here, we describe the development and characterization of ATM inhibitor molecules to enable in vivo proof-of-concept studies in HD animal models. Starting from previously reported ATM inhibitors, we aimed with few modifications to increase brain exposure by decreasing P-glycoprotein liability while maintaining potency and selectivity. Here, we report brain-penetrant ATM inhibitors that have robust pharmacodynamic (PD) effects consistent with ATM kinase inhibition in the mouse brain and an understandable pharmacokinetic/PD (PK/PD) relationship. Compound 17 engages ATM kinase and shows robust dose-dependent inhibition of X-ray irradiation-induced KAP1 phosphorylation in the mouse brain. Furthermore, compound 17 protects against mHTT (Q73)-induced cytotoxicity in a cortical-striatal cell model of HD.
- Published
- 2019